PMV Pharmaceuticals Inc（PMVP）财务数据PMVPPMV Pharmaceuticals Inc

Evaluating the bottom line, PMV Pharmaceuticals, Inc. maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -70.93%, provide a clear picture of how effectively PMVP converts its operational activities into shareholder value.

In the context of the broader market, PMVP competes directly with industry leaders such as HYFT and INMB. With a market capitalization of $97.41M, it holds a leading position in the sector. When comparing efficiency, PMVP's gross margin of N/A stands against HYFT's 60.63% and INMB's N/A. Such benchmarking helps identify whether PMV Pharmaceuticals, Inc. is trading at a premium or discount relative to its financial performance.

PMV Pharmaceuticals reported a net loss of $77.7 million for FY 2025, which is a 32.3% increase from the previous year's loss of $58.7 million. The company's cash position has also decreased significantly, from $183.3 million in 2024 to $112.9 million in 2025, indicating financial strain.